These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16507211)

  • 1. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy.
    Berthelot C; Cather J; Jones D; Duvic M
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):329-32. PubMed ID: 16507211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
    Smith EC; Riddle C; Menter MA; Lebwohl M
    Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
    Patel T; Gordon KB
    Dermatol Ther; 2004; 17(5):427-31. PubMed ID: 15379777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of remission of biologic agents for chronic plaque psoriasis.
    Langley RG; Gordon KB
    J Drugs Dermatol; 2007 Dec; 6(12):1205-12. PubMed ID: 18189060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
    Myers WA; Najarian D; Gottlieb AB
    J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis.
    Teraki Y; Tanaka S; Hitomi K; Izaki S
    Br J Dermatol; 2010 Dec; 163(6):1347-51. PubMed ID: 20731653
    [No Abstract]   [Full Text] [Related]  

  • 10. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al.
    Grinblat B; Scheinberg M
    Arthritis Rheum; 2005 Apr; 52(4):1333-4; author reply 1334. PubMed ID: 15818679
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary cutaneous aggressive epidermotropic CD4/CD8 double-negative cytotoxic T-cell lymphoma.
    Akkari H; Belhadjali H; Moussa A; Youssef M; Zili J
    Pathologica; 2012 Apr; 104(2):78-81. PubMed ID: 22953504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
    Brown SL; Greene MH; Gershon SK; Edwards ET; Braun MM
    Arthritis Rheum; 2002 Dec; 46(12):3151-8. PubMed ID: 12483718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
    Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological therapy and nail psoriasis.
    Lawry M
    Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case reports: practical experience with efalizumab in hand and foot psoriasis.
    Cohen DJ; Scherschun L
    J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell clone associated with efalizumab therapy.
    Lynch M; Murphy K; Slaby J; Kirby B
    Clin Exp Dermatol; 2011 Jan; 36(1):99-100. PubMed ID: 20545952
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis.
    Krathen MS; Gottlieb AB; Mease PJ
    J Rheumatol; 2010 Nov; 37(11):2205-15. PubMed ID: 20810498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.